+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating etavopivat, a new oral medicine being developed for blood disorders such as sickle cell disease and thalassaemia. These inherited conditions affect hemoglobin, the protein responsible for carrying oxygen in the body. This long-term study aims to assess the safety and effectiveness of etavopivat treatment over a period of up to 264 weeks, or until the drug is approved in the participants country. Participants will receive one of several oral doses of etavopivat, with dosing adjusted by age those 12 years and older will receive Etavopivat A or C, while children younger than 12 years will receive Etavopivat B. The study involves multiple groups including adults, adolescents, and children with different types of sickle cell disease or thalassaemia. All participants have completed a prior etavopivat treatment study and are continuing treatment in this rollover study. During the study, participants will be regularly monitored for treatment-related side effects and clinical benefits. Researchers will track adverse events, blood crisis rates, hemoglobin levels, hospitalizations, and blood transfusion needs. The study includes long-term safety and efficacy assessments conducted over several years, with monitoring continuing until study completion or drug approval. Participants health and treatment responses will be carefully followed throughout this extended period.

Age: 2Years +All GendersPhase 3
107 locations
G

Actively Recruiting

Researchers are evaluating etavopivat in adolescents and adults with sickle cell disease to see if it can reduce vaso-occlusive crises painful blockages in blood vessels and protect organs from damage. This phase 3 study will also assess whether etavopivat improves exercise tolerance and reduces fatigue compared to a placebo. The trial is randomized, double-blind, and placebo-controlled to ensure unbiased results on the medications effects. Participants will be randomly assigned to receive either oral etavopivat or a matching placebo. The study treatment is taken by mouth, and participants will be followed closely for about 2 years. This includes monitoring during the treatment period and ongoing assessments to evaluate the drugs impact on sickle cell disease symptoms and related health measures. Throughout the study, participants will undergo evaluations such as blood tests to measure hemoglobin and other markers, 6-minute walking tests to assess exercise capacity, and fatigue questionnaires. Researchers will track the number of vaso-occlusive crises requiring medical contact over 52 weeks as the primary outcome. Safety and efficacy will be monitored regularly, with follow-up continuing until the study ends approximately 4 years after enrollment begins.

Age: 12Years +All GendersPhase 3
175 locations
E

Actively Recruiting

Researchers are evaluating the pharmacokinetics and safety of etavopivat in children with sickle cell disease SCD. The study involves pediatric participants ranging in age from 6 months to less than 18 years and is designed as a phase 2, open-label, single-group study. Participants will be enrolled in age-based cohorts starting with the oldest group, with younger groups added sequentially after reviewing safety and pharmacokinetic data from prior cohorts. Participants will receive oral etavopivat once daily as either tablets or granules. The treatment includes a primary period lasting 24 weeks, followed by a 72-week extension period to further assess long-term safety and pharmacokinetics. The total study duration for each participant is approximately 96 weeks. Four age cohorts are studied 12 to less than 18 years, 6 to less than 12 years, 2 to less than 6 years, and 6 months to less than 2 years. Throughout the study, participants will be closely monitored with blood tests measuring etavopivat levels and hemoglobin changes, assessments of vaso-occlusive crisis frequency, and fatigue scales. Safety is evaluated by tracking adverse events, dose changes, and treatment interruptions. Transcranial Doppler ultrasound is used to assess cerebral blood flow at scheduled visits. The study includes frequent evaluations during both treatment periods to understand the drugs effects and safety in this young population.

Age: 6Months - 18YearsAll GendersPhase 2
18 locations
T

Actively Recruiting

Researchers are evaluating a new targeted therapy approach for solid tumors, including colorectal, lung, breast, and ovarian cancers. This trial focuses on combining two drugs, Palbociclib, a CDK46 inhibitor that disrupts cancer cell growth, and Bevacizumab, an anti-VEGF agent that blocks blood vessel formation supporting tumors. The study also investigates the role of Long Non-Coding RNAs LncRNAs as biomarkers to personalize treatment based on molecular profiles, aiming for improved outcomes and survival. Participants receive combined therapy with Palbociclib and Bevacizumab, tailored based on their LncRNA risk allele status and prior chemotherapy treatment. Four groups are formed carriers and non-carriers of the risk allele, each receiving either first-line combined therapy without prior chemotherapy or second-line therapy after chemotherapy. Palbociclib is given orally at 125 mg daily for 21 days every 28 days, while Bevacizumab is administered at 10 mgkg every 21 days. Throughout the study, patients undergo thorough assessments before and after treatment, including tumor progression, treatment response, survival rates, and thromboembolic events. Researchers also measure immune checkpoint expression and tumor proliferation markers over up to 60 months. The trial uses a randomized design with single masking to monitor the safety and effectiveness of this dual-targeted treatment strategy for solid tumors.

Age: 18Years +All GendersPhase 1
2 locations
L

Actively Recruiting

This research focuses on patients with sickle cell disease SCD who have previously taken part in a Novartis-sponsored study using crizanlizumab. The study provides continued access to crizanlizumab for those who are benefiting from the treatment as judged by their doctor. It is a multi-center and multi-national phase IV rollover study aimed at offering ongoing treatment options for these patients. Participants will continue receiving crizanlizumab at the same dose and schedule they had in their prior study. There is no screening period since patients transfer directly from the parent studies. After giving consent, treatment should begin as soon as possible, following the last dose schedule from the parent study. The study will remain open for up to 10 years or until the treatment becomes commercially available and reimbursed, or when the patients no longer need crizanlizumab. During the study, participants will have regular visits to monitor safety and treatment effects. A safety follow-up visit is planned 105 days after the last dose for those who stop treatment. However, this follow-up is not required if patients continue treatment commercially or through approved plans. Researchers will track any treatment-related side effects from the first dose until 105 days after the last dose. Overall participation duration varies based on treatment continuation and availability.

Age: 6Months - 100YearsAll GendersPhase 4
31 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are studying XmAb942 in a combined Phase 1 and Phase 2 clinical trial involving healthy volunteers and participants with moderately to severely active ulcerative colitis UC. The study aims to evaluate the safety, how the body processes the drug, and how the drug affects the body in healthy individuals, followed by assessing XmAb942s effects in people with UC. This trial is randomized, double-blind, and placebo-controlled, designed to understand the treatments potential in UC. The study has three parts. Part A involves single ascending doses of XmAb942 or placebo given subcutaneously or intravenously to healthy volunteers. Part B includes multiple ascending doses administered intravenously to healthy volunteers. Part C enrolls participants with active UC to receive three different doses of XmAb942 or placebo during a 12-week induction period, followed by a 40-week maintenance period with a single XmAb942 dose, then a 36-week follow-up. Participants will attend scheduled visits for dosing and monitoring throughout the study. Researchers will assess safety by tracking adverse events in healthy volunteers and clinical remission in UC patients using the modified Mayo score and endoscopic evaluation. Additional blood tests will measure drug levels and effects. The total participation duration can extend up to about 72 weeks for UC patients, including treatment and follow-up periods.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
114 locations